Clinical trials: Macular Degeneration Advanced
Dry Age-related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry.
- Trial name
- NCT03144999
- Testing
- AAVCAGsCD59
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Von Hippel-Lindau Syndrome
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
This study will examine whether he drug ranibizumab can slow or stop the growth of angiomas (blood vessel tumors) in patients with Von Hippel-Lindau syndrome (VHL).
- Trial name
- NCT00089765
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Corneal Deformity, Macular Degeneration Advanced
Comparison of Ocular Changes by Surgical Menopause Using Optical Coherence Tomography (OCT)
The aim of this study is to investigate the early changes in macular thickness, corneal thickness and intraocular pressure in young women undergoing surgical menopause.
- Conditions
- Corneal Deformity, Macular Degeneration Advanced, Surgical Menopause
- Trial name
- NCT05920655
- Testing
- Optic coherence tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Batman Training and Research Hospital
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Macular Degeneration, Age-related, Geographic Atrophy
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan.
- Trial name
- VERDANT (NCT06722157)
- Testing
- BI 771716, Pegcetacoplan
- Where
- 46 sites in United States
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Advanced Dry Macular Degeneration
Alpha MSH in Ocular Disease
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease.
- Trial name
- NCT03451578
- Testing
- Alpha MSH assay
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Duke University
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Cataract, Macular Degeneration Advanced
Cataract Surgery on Advanced Age Related Macular Degeneration Patients
The degree at which cataract surgery improves visual function in patients with advanced age-related macular degeneration (Advanced AMD) has been an on-going topic of discussion.
- Trial name
- NCT04045704
- Testing
- Cataract Surgery
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of British Columbia
Dry Macular Degeneration, Geographic Atrophy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular…
- Trial name
- NCT02590692
- Testing
- CPCB-RPE1
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regenerative Patch Technologies, LLC
AMD - Age-Related Macular Degeneration, Anxiety
Visual Rehabilitation and Depression in Visually Impaired Patients With AMD
Purpose: The aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced AMD by the use of questionnaires on the anxiety and depression status.
- Conditions
- AMD - Age-Related Macular Degeneration, Anxiety, Depression Disorders
- Trial name
- RET 06-24 (NCT06906003)
- Testing
- visual rehabilitation program
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Age-related Macular Degeneration
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT02873351
- Testing
- carbidopa-levodopa 25-100 mg
- Where
- United States
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
- Trial name
- P52901 (NCT01033721)
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Paloma Pharmaceuticals, Inc.
Macular Degeneration Advanced, Macular Degeneration, Senile
Visual Rehabilitation Through Acoustic Biofeedback With Retimax Vision Trainer in Patients With Advanced Age-related Macular Degeneration
At present there are no real therapies able to improve visual performance in patients with age-related macular degeneration, atrophic type.
- Conditions
- Macular Degeneration Advanced, Macular Degeneration, Senile, Macular Degeneration, Dry, Macular Scar
- Trial name
- NCT04084587
- Testing
- Retimax Vision Trainer
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- University of Modena and Reggio Emilia
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
AMD - Age-Related Macular Degeneration
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular…
- Trial name
- NCT07418177
- Testing
- hiPSC-RPEs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Age-related Macular Degeneration, Geographic Atrophy
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
- Trial name
- NCT05380492
- Testing
- VOY-101
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Perceive Biotherapeutics, Inc.